Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.

Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.

Flagship Pioneering

Casdin Capital

Invus

Irving Investors

Happy New Year from all of us at Foghorn! As we kick off 2024, we look forward to the year ahead as we continue to advance our mission to transform patient’s lives by correcting abnormal gene expression. #biotechnology #innovation #oncology

Check out photos of our Foghorn team, who had fun swapping surprises at our end of year holiday party. From all of us at Foghorn, wishing everyone a healthy and happy holiday season! #HappyHolidays

That's a wrap on the 65th Annual American Society of Hematology Meeting! Our team enjoyed coming together with the scientific community to present data and talk about our novel approach to modulating the chromatin regulatory system. Read all of our recent data presentations from #ASH23 and beyond: https://bit.ly/3GJ2vkZ

Martin (Murphy) Hentemann Kathleen Healy Caroline Almon #biotechnology #innovation #TPD

Meet Alexia Kalogeropulou, one of our brilliant scientists at Foghorn. Alexia shares why she loves the collaborative culture that enables us to advance our mission to transform the lives of people living with a wide spectrum of diseases. #LifeAtFoghorn #WomenInSTEM #biotechnology

Join us at the 2nd Annual TPD Assay Development & Screening Summit, where our Head of #DrugDiscovery, Marina Nelen, will be part of a panel to discuss high-throughput screening approaches and applications of assay techniques to degrader triage and profiling. See the agenda: https://ow.ly/J9Bh50QfwVc
#biotechnology #innovation #proteindegradation

We’re looking forward to the 65th American Society of Hematology Annual Meeting and Exposition, where clinical data from the Phase 1 dose-escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented. Learn more: https://ow.ly/wc3q50Qel4h
#ASH23

We know that our people are the key to our success, which is why we embrace a people first culture. Our culture is just one reason that Madeleine Henley was drawn to Foghorn. Learn more about our culture: https://ow.ly/Ca4050Qe2u8 

#LifeAtFoghorn #WomenInSTEM

Happy #Thanksgiving to all! Today, we are especially thankful for the incredible Foghorn team and their unwavering commitment to our mission of transforming lives across a wide spectrum of diseases. #biotechnology #innovation

Last week, we had the pleasure of joining other leading experts in the chromatin and epigenetics field during #Epi2023, where Dave Lahr gave a presentation on our preclinical work during a session on the nucleosome and chromatin remodeling. Find all our recent data presentations here: https://lnkd.in/gUtu9Wfi

#biotechnology #oncology #innovation

Congratulations to this year's recipients of the 2023 Paul Marks Prize for Cancer Research, including our scientific co-founder, Cigall Kadoch! This award underscores the important work being done at Foghorn to address breakdowns in the chromatin regulatory targets to advance novel treatments in cancer and beyond. #oncology #cancerresearch #innovation

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-26.34M -	-51.13M 94.13%	-68.80M 34.56%	-101.32M 47.27%	-108.88M 7.46%	-98.43M 9.60%
depreciation and amortization	379K -	693K 82.85%	1.33M 91.49%	3.23M 143.18%	3.32M 2.91%	8.66M 160.79%
deferred income tax	30K -	10K 66.67%	84K 740%	1.41M 1,580.95%		-846K -
stock based compensation	732K -	1.69M 131.42%	2.96M 74.79%	8.38M 183.15%	14.34M 70.99%	16.19M 12.90%
change in working capital	2.42M -	1.20M 50.62%	28.70M 2,297.91%	33.44M 16.51%	281.55M 741.92%	-41.88M 114.87%
accounts receivables				-300M -	300M 200%
inventory				-3.17M -
accounts payables	1.28M -	1.21M 5.09%	474K 60.86%	135K 71.52%	1.61M 1,095.56%	846K 47.58%
other working capital	1.15M -	-14K 101.22%	28.23M 201,735.71%	336.48M 1,091.96%	-20.07M 105.96%	-42.73M 112.90%
other non cash items	124K -	1.20M 866.94%	4.44M 270.23%	4.61M 3.76%	3.29M 28.55%	-1.80M 154.76%
net cash provided by operating activities	-22.65M -	-46.34M 104.59%	-31.29M 32.48%	-50.25M 60.61%	193.61M 485.30%	-118.11M 161.00%
investments in property plant and equipment	-1.54M -	-968K 37.18%	-16.18M 1,571.80%	-3.31M 79.53%	-1.21M 63.48%	-1.22M 1.16%
acquisitions net		4K -	250K 6,150%	-39.49M 15,894.40%	243.11M 715.69%
purchases of investments			-92.98M -	-99.98M 7.53%	-409.35M 309.41%	-73.90M 81.95%
sales maturities of investments			-250K -	139.47M 55,888%	166.23M 19.19%	219.57M 32.09%
other investing activites			250K -	39.49M 15,694.40%	-243.11M 715.69%
net cash used for investing activites	-1.54M -	-964K 37.44%	-108.91M 11,198.13%	36.17M 133.21%	-244.32M 775.43%	144.45M 159.12%
debt repayment	-823K -	-7.98M 870.11%	-15.53M 94.51%	-21.20M 36.54%
common stock issued		15.98M -	122.12M 663.97%	42.20M 65.44%	1.76M 95.82%	1.78M 0.85%
common stock repurchased
dividends paid
other financing activites	52.59M -	15.97M 69.64%	110.88M 594.40%	1.42M 98.72%
net cash used provided by financing activities	51.77M -	23.97M 53.70%	217.47M 807.31%	22.42M 89.69%	1.76M 92.14%	1.78M 0.85%
effect of forex changes on cash
net change in cash	27.58M -	-23.33M 184.59%	77.27M 431.22%	8.34M 89.21%	-48.95M 686.82%	28.12M 157.45%
cash at beginning of period	13.00M -	40.59M 212.10%	17.25M 57.48%	94.53M 447.83%	102.87M 8.82%	52.21M 49.24%
cash at end of period	40.59M -	17.25M 57.48%	94.53M 447.83%	102.87M 8.82%	53.92M 47.58%	80.34M 48.99%
operating cash flow	-22.65M -	-46.34M 104.59%	-31.29M 32.48%	-50.25M 60.61%	193.61M 485.30%	-118.11M 161.00%
capital expenditure	-1.54M -	-968K 37.18%	-16.18M 1,571.80%	-3.31M 79.53%	-1.21M 63.48%	-1.22M 1.16%
free cash flow	-24.19M -	-47.30M 95.56%	-47.47M 0.35%	-53.56M 12.84%	192.40M 459.21%	-119.33M 162.02%

NASDAQ:FHTX

Foghorn Therapeutics Inc.

Last Close

5.81

17/05 20:00

Market Cap

128.76M

Beta: 2.16

Volume Today

59.69K

Avg: 76.72K

PE Ratio

−1.07

PFCF: −0.97